http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 16 Jan 2026 16:45:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html <p align="justify">CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PNbUYxmiXFw7qiEMh55dTl3MPxDiCeSM2epMSmngbw8GSP2wLh7nsWbeJwuADC8LXhNRPJXU0vBw5Mxir3d-I1lSQncFXacWwNSXfAYnznGysCToHmhb5maLfAKcXkkBVsu6zvnguEsuGS_HubbZ9xjLi7HAWsPlKLfE3FXvIKf4MiygunuXxhA4Ofr1OBdLAngaeuE4ZiNzn3rcWQ0Z4zZUzQRCn9VskFYzBATyuB-e23YCKXN8xwo9_l8lh_nt" rel="nofollow" target="_blank">LFCR</a>) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, http://www.streetinsider.com/Press+Releases/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html Fri, 16 Jan 2026 16:45:00 -0500 LFCR NBI O.00086214 http://www.streetinsider.com/Press+Releases/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html <p align="justify">CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PNbUYxmiXFw7qiEMh55dTl3MPxDiCeSM2epMSmngbw8GSP2wLh7nsWbeJwuADC8LXhNRPJXU0vBw5Mxir3d-I1lSQncFXacWwNSXfAYnznGysCToHmhb5maLfAKcXkkBVsu6zvnguEsuGS_HubbZ9xjLi7HAWsPlKLfE3FXvIKf4MiygunuXxhA4Ofr1OBdLAngaeuE4ZiNzn3rcWQ0Z4zZUzQRCn9VskFYzBATyuB-e23YCKXN8xwo9_l8lh_nt" rel="nofollow" target="_blank">LFCR</a>) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, http://www.streetinsider.com/Press+Releases/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html Fri, 16 Jan 2026 16:45:00 -0500 LFCR NBI O.00086214 http://www.streetinsider.com/Press+Releases/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html <p align="justify">CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PNbUYxmiXFw7qiEMh55dTl3MPxDiCeSM2epMSmngbw8GSP2wLh7nsWbeJwuADC8LXhNRPJXU0vBw5Mxir3d-I1lSQncFXacWwNSXfAYnznGysCToHmhb5maLfAKcXkkBVsu6zvnguEsuGS_HubbZ9xjLi7HAWsPlKLfE3FXvIKf4MiygunuXxhA4Ofr1OBdLAngaeuE4ZiNzn3rcWQ0Z4zZUzQRCn9VskFYzBATyuB-e23YCKXN8xwo9_l8lh_nt" rel="nofollow" target="_blank">LFCR</a>) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, http://www.streetinsider.com/Press+Releases/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html Fri, 16 Jan 2026 16:45:00 -0500 LFCR NBI O.00086214 http://www.streetinsider.com/Globe+Newswire/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html <p align="justify">CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PNbUYxmiXFw7qiEMh55dTl3MPxDiCeSM2epMSmngbw8GSP2wLh7nsWbeJwuADC8LXhNRPJXU0vBw5Mxir3d-I1lSQncFXacWwNSXfAYnznGysCToHmhb5maLfAKcXkkBVsu6zvnguEsuGS_HubbZ9xjLi7HAWsPlKLfE3FXvIKf4MiygunuXxhA4Ofr1OBdLAngaeuE4ZiNzn3rcWQ0Z4zZUzQRCn9VskFYzBATyuB-e23YCKXN8xwo9_l8lh_nt" rel="nofollow" target="_blank">LFCR</a>) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, http://www.streetinsider.com/Globe+Newswire/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html Fri, 16 Jan 2026 16:45:00 -0500 LFCR NBI O.00086214 http://www.streetinsider.com/Globe+Newswire/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html <p align="justify">CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PNbUYxmiXFw7qiEMh55dTl3MPxDiCeSM2epMSmngbw8GSP2wLh7nsWbeJwuADC8LXhNRPJXU0vBw5Mxir3d-I1lSQncFXacWwNSXfAYnznGysCToHmhb5maLfAKcXkkBVsu6zvnguEsuGS_HubbZ9xjLi7HAWsPlKLfE3FXvIKf4MiygunuXxhA4Ofr1OBdLAngaeuE4ZiNzn3rcWQ0Z4zZUzQRCn9VskFYzBATyuB-e23YCKXN8xwo9_l8lh_nt" rel="nofollow" target="_blank">LFCR</a>) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, http://www.streetinsider.com/Globe+Newswire/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html Fri, 16 Jan 2026 16:45:00 -0500 LFCR NBI O.00086214 http://www.streetinsider.com/Globe+Newswire/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html <p align="justify">CHASKA, Minn., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=PNbUYxmiXFw7qiEMh55dTl3MPxDiCeSM2epMSmngbw8GSP2wLh7nsWbeJwuADC8LXhNRPJXU0vBw5Mxir3d-I1lSQncFXacWwNSXfAYnznGysCToHmhb5maLfAKcXkkBVsu6zvnguEsuGS_HubbZ9xjLi7HAWsPlKLfE3FXvIKf4MiygunuXxhA4Ofr1OBdLAngaeuE4ZiNzn3rcWQ0Z4zZUzQRCn9VskFYzBATyuB-e23YCKXN8xwo9_l8lh_nt" rel="nofollow" target="_blank">LFCR</a>) (“Lifecore”) a fully integrated contract development and manufacturing organization (“CDMO”), today announced that on January 14, 2026, the Lifecore compensation committee approved grants under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) of restricted stock unit (“RSU”) awards with respect to an aggregate 1,738 shares of its common stock and stock options for an aggregate 8,775 shares of common stock to two newly hired employees of Lifecore. The RSU award and stock options were granted on January 14, 2026, http://www.streetinsider.com/Globe+Newswire/Lifecore+Announces+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/25860896.html Fri, 16 Jan 2026 16:45:00 -0500 LFCR NBI O.00086214 http://www.streetinsider.com/Press+Releases/AtaiBeckley+Added+to+the+Nasdaq+Biotechnology+Index+%28NBI%29/25773011.html <p align="justify">NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025.</p> <p align="justify">“2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pipeline and corporate foundation. We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs http://www.streetinsider.com/Press+Releases/AtaiBeckley+Added+to+the+Nasdaq+Biotechnology+Index+%28NBI%29/25773011.html Tue, 23 Dec 2025 07:00:00 -0500 ATAI NBI http://www.streetinsider.com/Press+Releases/AtaiBeckley+Added+to+the+Nasdaq+Biotechnology+Index+%28NBI%29/25773011.html <p align="justify">NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025.</p> <p align="justify">“2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pipeline and corporate foundation. We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs http://www.streetinsider.com/Press+Releases/AtaiBeckley+Added+to+the+Nasdaq+Biotechnology+Index+%28NBI%29/25773011.html Tue, 23 Dec 2025 07:00:00 -0500 ATAI NBI http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Added+to+the+Nasdaq+Biotechnology+Index+%28NBI%29/25773011.html <p align="justify">NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025.</p> <p align="justify">“2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pipeline and corporate foundation. We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Added+to+the+Nasdaq+Biotechnology+Index+%28NBI%29/25773011.html Tue, 23 Dec 2025 07:00:00 -0500 ATAI NBI http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Added+to+the+Nasdaq+Biotechnology+Index+%28NBI%29/25773011.html <p align="justify">NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced its common stock has been added to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 22, 2025.</p> <p align="justify">“2025 has been a defining year for AtaiBeckley, marked by meaningful progress across our pipeline and corporate foundation. We strengthened our balance sheet by raising approximately $300 million, advanced multiple clinical programs http://www.streetinsider.com/Globe+Newswire/AtaiBeckley+Added+to+the+Nasdaq+Biotechnology+Index+%28NBI%29/25773011.html Tue, 23 Dec 2025 07:00:00 -0500 ATAI NBI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Press+Releases/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html <p> LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading on Friday, December 19, 2025. </p><p> “Our inclusion in the Nasdaq Biotechnology Index is an important recognition of Puma’s continued commercial execution, profitability, and clinical progress,” said Alan H. Auerbach, Chairman, Chief Executive Officer, and President of Puma. “With sustained demand for NERLYNX® and advancing development of alisertib, we believe this milestone enhances our visibility within the biotechnology investment community as we remain focused on delivering value for patients http://www.streetinsider.com/Business+Wire/Puma+Biotechnology+Added+to+the+NASDAQ+Biotechnology+Index+%28NBI%29/25770783.html Mon, 22 Dec 2025 16:10:00 -0500 A.06822034 A.60012004 NBI O.01304637 O.13305050 O.20026344 PBYI http://www.streetinsider.com/Index+Changes/Aclaris+Therapeutics+added+to+NASDAQ+Biotechnology+Index/25764724.html <p>Aclaris Therapeutics Inc. (NASDAQ: ACRS) has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI), effective at the close of trading on December 19, 2024, according to a company statement.</p><p>The clinical-stage biopharmaceutical company focuses on developing product candidates for immuno-inflammatory diseases. Aclaris is based in Wayne, Pennsylvania.</p><p>The NBI tracks the performance of securities listed on The NASDAQ Stock Market that are classified as biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies must meet specific eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company.</p><p>The index is evaluated annually in December and http://www.streetinsider.com/Index+Changes/Aclaris+Therapeutics+added+to+NASDAQ+Biotechnology+Index/25764724.html Fri, 19 Dec 2025 16:01:48 -0500 ACRS NBI